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Summary
Background Most uterine cervical high-risk human papillomavirus (HPV) infections are transient, with only a small 
fraction developing into cervical cancer. Family aggregation studies and heritability estimates suggest a significant 
inherited genetic component. Candidate gene studies and previous genome-wide association studies (GWASs) report 
associations between the HLA region and cervical cancer. Adopting a genome-wide approach, we aimed to compare 
genetic variation in women with invasive cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 with that 
in healthy controls.
Methods We did a GWAS in a cohort of unrelated European individuals using data from UK Biobank, a population-
based cohort including 273 377 women aged 40–69 years at recruitment between March 13, 2006, and Oct 1, 2010. 
We used an additive univariate logistic regression model to analyse genetic variants associated with invasive cervical 
cancer or CIN3. We sought replication of candidate associations in FinnGen, a large independent dataset of 
128 123 individuals. We also did a two-sample mendelian randomisation approach to explore the role of risk factors in 
the genetic risk of cervical cancer.
Findings We included 4769 CIN3 and invasive cervical cancer case samples and 145 545 control samples in the 
GWAS. Of 9 600 464 assayed and imputed single-nucleotide polymorphisms (SNPs), six independent variants 
were associated with CIN3 and invasive cervical cancer. These included novel loci rs10175462 (PAX8; odds 
ratio [OR] 0·87, 95% CI 0·84–0·91; p=1·07 × 10–⁹) and rs27069 (CLPTM1L; 0·88, 0·84–0·92; p=2·51 × 10–⁹), and 
previously reported signals at rs9272050 (HLA-DQA1; 1·27, 1·21–1·32; p=2·51 × 10–²⁸), rs6938453 (MICA; 
0·79, 0·75–0·83; p=1·97 × 10–¹⁷), rs55986091 (HLA-DQB1; 0·66, 0·60–0·72; p=6·42 × 10–²²), and rs9266183 
(HLA-B; 0·73, 0·64–0·83; p=1·53 × 10–⁶). Three SNPs were replicated in the independent Finnish dataset 
of 1648 invasive cervical cancer cases: PAX8 (rs10175462; p=0·015), CLPTM1L (rs27069; p=2·54 × 10–⁷), and 
HLA-DQA1 (rs9272050; p=7·90 × 10–⁸). Mendelian randomisation further supported the complementary role of 
smoking (OR 2·46, 95% CI 1·64–3·69), older age at first pregnancy (0·80, 0·68–0·95), and number of sexual 
partners (1·95, 1·44–2·63) in the risk of developing cervical cancer.
Interpretation Our results provide new evidence for the genetic susceptibility to cervical cancer, specifically the 
PAX8, CLPTM1L, and HLA genes, suggesting disruption in apoptotic and immune function pathways. Future 
studies integrating host and viral, genetic, and epigenetic variation, could further elucidate complex host–viral 
interactions.
Funding NIHR Imperial BRC Wellcome 4i Clinician Scientist Training Programme.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Despite the introduction of screening and vaccination 
programmes, invasive cervical cancer remains one of the 
most common malignancies in women globally. Persistent 
infection with oncogenic high-risk human papillomavirus 
(HPV) subtypes is necessary for the development of 
cervical cancer and its precursor cervical intraepithelial 
neoplasia (CIN).1 HPV infection is common, with a life-
time incidence over 70%.2 Most infections are transient 
and cleared through an incompletely understood immune 
response, but a fraction of infected women develop a 
persistent HPV infection, which ultimately progresses to 
CIN or invasive cervical cancer.3
A number of factors, both host and viral, have been 
reported to affect HPV clearance and the risk of 
progression to cervical cancer. HPV genotype, HPV 
genetic and epigenetic variation,4 and viral load have been 
shown to affect disease outcome. Host behavioural and 
environmental factors that might influence exposure to 
HPV or immune response to infection have been reported, 
including tobacco smoking,5 hormonal contraceptives, 
and socioeconomic, reproductive, and sexual factors.6 
Family-based studies have reported family aggregation of 
cervical cancer, but were not able to discriminate between 
the effect of genes and shared environmental factors.7,8 
Population-based studies provide evidence for a genetic 
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Research in context
Evidence before this study
The impact of genetic variance on predisposition to cervical 
cancer has long been debated and there remains uncertainty 
regarding the hereditary component of cervical malignancy. 
Family aggregation studies and heritability estimates suggest 
an inherited genetic contribution to disease risk of up 
to 27–36%. We searched PubMed and the GWAS Catalog with 
the terms “cervical cancer” OR “cervical intraepithelial 
neoplasia” OR “CIN” in combination with “genome-wide 
association” OR “GWAS”, for articles of any language, published 
from Jan 1, 1990, to April 16,2020, in which genes previously 
associated with risk of cervical precancer or cancer were 
identified. To our knowledge, seven previous genome-wide 
association studies of cervical preinvasive and invasive disease 
have been performed worldwide, with the most consistently 
identified signals in the HLA region. However, these studies 
were limited by modest sample sizes and by the low number of 
invasive cases included, with case phenotypes mainly including 
preinvasive disease. Because of the lack of formal replication, 
results have thus far been inconsistent in the literature and 
further work is required to characterise the genetic 
predisposition to cervical cancer.
Added value of this study
To our knowledge, this study presents results from the largest 
genetic association study to date, which explores both cervical 
preinvasive and invasive phenotypes and includes the largest 
analysis of invasive cervical cancer phenotypes. We expanded 
the study of genetic variants outside of the HLA region with a 
broad imputation and identified novel variants at genome-
wide significance in the PAX8 and CLPTM1L genes. Results were 
validated in a large independent replication set. Through 
mendelian randomisation, we were able to triangulate evidence 
independently linking cervical cancer risk to earlier age at 
first pregnancy, higher number of sexual partners, and exposure 
to tobacco smoking.
Implications of all the available evidence
Our results provide new evidence for genetic susceptibility to 
cervical cancer, suggesting disruption in apoptotic and immune 
function pathways at the PAX8, CLPTM1L, and HLA genes, 
and provide further insight into high-risk behavioural factors. 
Studies integrating analysis of host susceptibility and viral 
genetic variation, along with epigenetic behaviour, will further 
elucidate the differential risk associated with the complex 
host–viral interaction.




For more on the FinnGen study 
see https://www.finngen.fi/en/ 
for_researchers
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contribution (27% attributable fraction) to the development 
of cervical tumours,9 and report common variant-based 
heritability at 36%.10
Several candidate gene studies have explored genetic 
regions related to plausible immunological and carcino-
genic pathways (including the HLA region11), but have 
shown inconsistent results that frequently could not 
be replicated in larger cohorts. To our knowledge, 
seven genome-wide association studies (GWASs) have 
examined genetic variation in cervical precancer or 
cancer, including European,10,12 Chinese,13 and Japanese 
populations.14 These studies varied in size and reported a 
total of 112 single-nucleotide polymorphisms (SNPs) 
associated, at genome-wide significance level, with 
cervical disease. The most consistently identified allelic 
variation is at the 6p21.3 locus, within the HLA 
region,10,12,13 where 44 variants have been reported across 
six studies, and the MHC class I polypeptide-related 
sequence A (MICA) gene.10,12
Our study aimed to perform a genome-wide exploration 
of variants associated with invasive cervical cancer or 
high-grade preinvasive lesions (CIN grade 3 [CIN3]) 
using data from the UK Biobank; and to validate candidate 
associations in an independent population (FinnGen). 
Using a two-sample mendelian randomisation approach, 
we explored the role of the most established risk factors 
in the genetic risk of cervical cancer.
Methods
Study design and participants
We did a GWAS in female UK Biobank participants of 
European ancestry and with available genotyping 
data after quality control. The UK Biobank is a population-
based cohort of approximately 500 000 volunteers 
(n=273 377 women with genotyping data available), aged 
40–69 years at recruitment between March 13, 2006, and 
Oct 1, 2010 (appendix p 2).15
UK Biobank has approval from the North West 
multicentre Research Ethics Committee, which covers 
the UK. In Scotland, UK Biobank has approval from the 
Community Health Index Advisory Group.
The FinnGen study was used as a replication cohort. 
The FinnGen cohort (release 5) is a public–private 
partnership combining gentoyping data from Finnish 
Biobanks and digital health record data from Finnish 
health registries. Samples are made up of nine 
participating biobanks (Auria Biobank, Biobank Borealis 
of Northern Finland, Biobank of Eastern Finland, Central 
Finland Biobank, Finnish Clinical Biobank Tampere, 
Helsinki Biobank, Terveystalo Biobank, and THL 
Biobank). The cohort consists of a total of 218 792 
individuals at the latest data release on July 15, 2020.
The Coordinating Ethics Committee of the Hospital 
District of Helsinki and Uusimaa (HUS) approved the 
FinnGen study, protocol number HUS/990/2017.
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Procedures
We used existing genotype calls on DNA samples from 
female UK Biobank participants who were genotyped for 
820 967 variants using a custom Affymetrix UK Biobank 
Axiom array (Affymetrix Reseacher Services Laboratory, 
Santa Clara, CA, USA) and 807 411 variants using the 
BiLEVE Axiom array (Affymetrix Reseacher Services 
Laboratory) from the UK BiLEVE study. Imputation 
was done centrally according to HG37 Haplotype 
Reference Consortium and UK10K and 1000 Genomes 
project reference panels by UK Biobank, resulting in 
9 600 464 imputed common variants for analysis.
Samples that failed genotyping quality control, had 
high heterozygosity for autosomal chromosomes or 
missingness (samples identified as outliers in UK 
Biobank data field 22027), genetic sex discordance, high 
guanine–cytosine content, missing covariates, and 
duplicates were excluded from the present analysis. The 
resultant 235 716 samples were retained for analysis.
To reduce bias due to high degree of relatedness within 
the UK Biobank, we used a graph representation of the 
kinship between participants from UK Biobank kinship 
coefficient data to define a set of unrelated individuals of 
all ancestries (n=180 224; appendix p 3). To avoid bias 
from transethnic linkage disequilibrium pattern 
heterogeneity, data were restricted to the largest ethnic 
group, which was European ancestry (n=150 314). 
Ancestry was identified by genetic information, as 
extracted from UK Biobank field 22 006 (appendix p 3).
The primary disease traits studied consisted of 
diagnoses of both cervical cancer and carcinoma in situ 
(CIN3). Cervical cancer case samples were identified as 
either CIN3 or invasive cervical cancer using diagnoses 
from a series of predefined International Classification of 
Diseases codes via linkage to UK cancer registries 
(followed up to Dec 14, 2016) and hospital episode 
statistics (followed up to March 31, 2017; appendix pp 10–11). 
Controls (n=145 545) were identified as women with no 
record of or reported history of any cervical abnormality 
from nurse-administered questionnaires at recruitment 
and linkage to hospital episode statistics.
Genetic association analysis
The association study was done using an additive 
univariate logistic regression model analysing cervical 
cancer status as the outcome against each of the imputed 
SNPs using PLINK v1.9b3.3. To maximise statistical 
power, we adopted in our primary analyses a broad 
definition of cervical cancer including both CIN3 and 
invasive cervical cancer outcomes. To account for disease 
heterogeneity and progression, we subsequently analysed 
case samples from each subtype separately.
Regression models were adjusted for established 
confounders including age, smoking status (classified as 
never, former, or current, as obtained from UK Biobank 
field 20 116), social deprivation score (UK Biobank 
field 189), and in order to model technically induced 
nuisance variation, the analytical batch (UK Biobank 
field 22 000). Effect size estimates were expressed as odds 
ratio (OR) and 95% CI measuring risk change per copy of 
the minor allele. To control for population structure and 
covert relatedness, we adjusted our analyses for the first 
ten principal components as estimated by UK Biobank and 
capturing the study population latent genetic structure. We 
only considered SNPs with a minor allele frequency (MAF) 
greater than 1% (n=656 284 genotyped; 9 600 464 imputed). 
To control for multiple testing, we considered the 
established genome-wide significance level of 5 × 10–⁸.
We did a sensitivity analysis only considering genotyped 
variants (ie, discarding imputed genotypes). We did a 
series of conditional analyses to identify genetic variants 
that were independently associated with cervical cancer 
outcomes and complementarily contributed to the 
outcome explanation. For each chromosome separately, 
an iterative procedure was done that identified the 
SNP with the strongest association and conditioned the 
logistic regression model on that SNP. This procedure 
was repeated by sequentially conditioning on the 
strongest SNP in the chromosome and was continued 
until there were no remaining SNPs associated with the 
outcome. Conditional p values (pcond ) are defined for each 
SNP as the p value for the model adjusted for all other 
associated SNPs in the chromosome. We evaluated the 
novelty of our findings based on reported SNPs from the 
GWAS Catalog (accessed May 20, 2020) and accounted 
for a 1 Mb window. LocusZoom software (Original 
LocusZoom version) and visual inspection of heatmaps 
(generated in linkage disequilibrium based on the 
1000 Genomes project) were used to explore linkage 
disequilibrium blocks of SNPs identified in conditional 
analyses.
We did an independent validation of the conditional 
SNPs identified in our discovery dataset using the 
FinnGen release 5 dataset (replication cohort), in which a 
total of 655 973 genetic markers were assayed and 
imputed against a Finnish population-specific backbone 
(appendix p 4). These data include 4246 case samples 
from a Finnish population. Replication in the FinnGen 
release 5 dataset was sought for the SNPs and insertion–
deletions (indels) found to be genome-wide significant 
(p≤5 × 10–⁸) with a MAF of 1% or greater following 
conditional analysis in our discovery set, using a nominal 
significance level of p=0·05.
Functional analyses of variants and genes
To explore the phenotypic and functional effects of 
detected genetic loci, we used publicly available databases 
(Phenoscanner, UCSC genome browser, dbSNP, and 
ENCODE) to annotate variants. We searched for 
previously reported associations with other disease traits 
in the GWAS Catalog. We subsequently used publicly 
available datasets to explore potential carcinogenic 
pathways through the examination of gene expression in 
cervical cancer tissue, normal cervical tissue, and other 
For Phenoscanner see http://
www.phenoscanner.medschl.
cam.ac.uk
For UCSC genome browser see 
https://genome.ucsc.edu
For dbSNP see https://www.
ncbi.nlm.nih.gov/snp/
For ENCODE see https://www.
encodeproject.org
For PLINK v1.9b3.3 see https://
zzz.bwh.harvard.edu/plink
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tumour tissues (including expression quantitative trait 
loci [eQTL] ratios in the PanCanQTL database and the 
GTEx Portal). To establish if any gene already had a 
known role in cancer, we further searched somatic 
mutations (COSMIC) in cervical and other cancers. 
Intronic variants were further investigated for possible 
indirect effects on gene expression through transcription 
regulation including histone marks and motifs in 
HaploReg v4.1 (appendix p 5).
Mendelian randomisation
To quantify the contribution of established environ-
mental risk factors to the risk of cervical cancer, we did 
a two-sample mendelian randomisation using inde-
pendent (squared coefficient of correlation [r²]<0·001) 
genetic variants with known effects on the risk factors, 
as instruments for the exposure (at genome-wide 
significance).
We used the largest available datasets to seek genetic 
instruments of the most established risk factors: tobacco 
smoking, age at first pregnancy, and number of sexual 
partners (appendix pp 12, 13). In our two-sample 
mendelian ran domisation, we quantify the linear contri-
bution of these instruments to the genetically predicted 
risk of cervical cancer, as measured by log odds (log OR), 
using inverse variance weighting mendelian random-
isation to estimate effect size expressed as OR and 
95% CI. For exposures with significant effects in the 
main analysis (using Benjamini and Hochberg’s false-
discovery rate below 5%), we used a range of robust 
mendelian randomisation approaches to account for 
possible violations of the instrumental variable 
assumptions including weighted-median and mendelian 
randomisation-presso (appendix p 5). We subsequently 
did two multivariable mendelian random isation models 
(appendix p 5) to account for potential pleiotropy and 
attenuation when adjusting for age of first pregnancy 
or risky behaviours (ie, lifetime smoking index and 
number of sexual partners). For multivariable mendelian 
random isation, we used genetic variants associated with 
37 661 samples excluded due to genotyping quality control failure, high missingness
 or heterozygosity, sex discordance, or missing covariates
150 314 included in GWAS of European 
 ancestry
 4769 case samples and
 145 545 controls
 3853 SNPs and indels associated with risk
 of invasive cervical cancer or CIN3
FinnGen release 5 
1648 invasive cervical cancer case samples
 and 121 931 controls
 298 CIN3 case samples and 
 123 281 controls
4246 cervical dysplasia case samples and
 68 969 controls
Conditional analysis Post-GWAS analysis
6 SNPs in UK Biobank
3 SNPs in FinnGen release 5
Annotation
5 genes identified: PAX8, CLPTM1L, HLA-DR,
HLA-DQ, MICA
Functional analyses
eQTL chromosome 2 PAX8
Mendelian randomisation  
62 risk factors identified








273 377 women recruited aged 40–69 years
 and resident in the UK
21 914 withdrew consent and related individuals
235 716 remaining after quality control
63 488 excluded due to non-European ancestry
213 802 remaining after further exclusions
Figure 1: Analysis plans for the discovery (UK Biobank) and replication (FinnGen release 5) datasets
GWAS=genome-wide association study. CIN3=cervical intraepithelial neoplasia grade 3. SNP=single-nucleotide polymorphism. eQTL=expression quantitative 
trait loci.
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either of the two exposures as instrumental variables at 
genome-wide significance.
Role of the funding source
The funders had no role in the study design; in the 
collection, analysis, or interpretation of data; in the 
writing of the report; or in the decision to submit 
the paper for publication.
Results
From the original 235 716 female participants with 
genotyping and phenotypic data available in UK Biobank 
(after quality control), 85 402 were excluded, leaving 
150 314 women for subsequent analyses (4769 case 
samples [764 invasive cervical cancer and 4005 CIN3] and 
145 545 controls; figure 1; appendix p 8).
The GWAS identified 3853 SNPs and indels associated 
with the risk of invasive cervical cancer or CIN3. 
Functional analysis (appendix p 6) revealed that these 
associations targeted three genetic regions: the HLA 
region in which 3815 of the 3853 detected associations 
were located (chromosome 6: base pairs 31 324 647–
32 623 713), PAX8 (2q14.1; lead SNP rs10175462 [OR 0·87, 
95% CI 0·84–0·91]; p=1·07 × 10–⁹), and CLPTM1L (5p15.33; 
lead SNP rs27069 [0·88, 0·84–0·92]; p=2·51 × 10–⁹; 
appendix pp 14 and 118). There was minimal evidence of 
genomic inflation (appendix p 119).
When restricting the phenotype to invasive cervical 
cancer case samples only (n=764), signals in the PAX8 and 
HLA regions were attenuated and did not reach the 
genome-wide significance level, and a novel locus was 
detected at 12q24.11 (rs117960705; OR 2·41 [95% CI 
1·81–3·23]; p=2·76 × 10–⁹) located in the ACACB gene 
(appendix p 120). In a comparative random subset of 
764 CIN3 cases, previously detected PAX8 signals were no 
longer apparent, while HLA loci remained associated with 
CIN3 at a genome-wide significance level (appendix p 120).
In the 9 600 464 assayed and imputed variants, 
conditional analyses identified six loci independently 
associated with CIN3 or invasive cervical cancer (table). 
This included one signal in chromosome 2 (driving SNP 
rs10175462 and indel 113992800_TCC_T; PAX8), one in 
chro mosome 5 (driving SNP rs27069; CLPTM1L), and 
four inde pendent signals in the HLA region: 
three common non-coding variants rs9272050 (HLA-
DQA1; OR 1·27 [95% CI 1·21–1·32]; p=2·51 × 10–²⁸), 
rs6938453 (MICA; OR 0·79 [0·75–0·83]; p=1·97 × 10–¹⁷), 
and rs55986091 (HLA-DQB1; 0·66 [0·60–0·72]; 
p=6·42 × 10–²²), and one low-frequency missense variant 
in the HLA-B gene rs9266183 (0·73 [0·64–0·83]; 
p=1·53 × 10–⁶; ORcond 0·68 [0·59–0·77]; pcond=6·20 × 10–⁹ 
MAF 0·04 in Europeans). Conditional analyses identified 
rs117960705 (chromosome 12) as the only variant 
independently associated with the invasive cervical 
cancer outcome, and rs150406145 (chromosome 2) and 
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Regional plots of sentinel SNPs further showed single 
signals at the PAX8 and CLPTM1L genes (figure 2A, B), 
whereas associations in the HLA were tightly clustered 
(figure 2C, D). Exploration of the linkage disequilibrium 
structures of conditional signals showed single blocks 
in chromosomes 2 and 5, and a complex linkage 
disequilibrium structure in the HLA region (appendix 
p 121). Comparison of the three remaining conditionally 
associated SNPs in the HLA-DQA1, HLA-DQB1, and 
MICA with GWAS Catalog suggests they had not been 
previously identified, but were in high linkage disequili-





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A Chromosome 2 rs10175462 (PAX8)
























































B Chromosome 5 rs27069 (CLPTM1L)
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Figure 2: Regional plots of sentinel SNPs from conditional analysis associated with CIN3 and invasive cervical cancer in PAX8 (chromosome 2; A), CLPTM1L 
(chromosome 5; B), and HLA (chromosome 6; C and D)
The p value of the association between variant and the cervical cancer status is represented by the log₁₀ scale (y-axis) in function of the genetic location. SNPs are colour 
coded in relation to their correlation (as measured by their recombination rate [r²]) with the sentinel SNP (shown in red) in the region. In the lower panel of each plot, 
gene annotations are provided according to the 1000 Genomes project 2014. SNP=single nucleotide polymorphism. CIN3=cervical intraepithelial neoplasia grade 3.
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The HLA-B low-frequency missense variant rs9266183 
was not identified (to our knowledge) by any previous 
study (appendix p 97).
Analysis restricted to genotyped variants revealed the 
same pattern of association as the imputed and 
genotyped variants in HLA and PAX8 regions, but the 
signal in CLPTM1L no longer reached the genome-wide 
signifi cance level (appendix p 122).
In FinnGen release 5, in the absence of detailed 
information on disease subtypes, we did three separate 
GWASs of cervical precancer and cancer phenotypes 
including a total of 128 123 participants. We investigated 
separately the cervical dysplasia outcome (n=4246, 
including mainly CIN3 but also CIN1–2 case samples, 
appendix p 4), CIN3 outcome (n=298), and invasive 
cervical cancer outcome (n=1648).
Of our six conditional loci, three were assayed in the 
FinnGen release 5 dataset (PAX8 rs10175462 [and indel 
rs35724515]; CLPTM1L rs27069; and HLA-DQA1 
rs9272050). Replication was achieved for the PAX8 SNP 
rs10175462 (and indel rs35724515) for invasive cervical 
cancer (p=0·015) and cervical dysplasia (p=0·0002) 
pheno types with concordant direction of effect. No effect 
of rs10175462 on the CIN3 phenotype was observed 
(p=0·069; OR 0·86, 95% CI 0·73–1·01; appendix p 112). 
The significant association of HLA-DQA1 lead SNP 
(rs9272050) was replicated in invasive cervical cancer 
(p=7·90 × 10–⁸), CIN3 (p=0·0005), and cervical dysplasia 
(p=5·33 × 10–¹⁰) phenotypes. Lead SNP rs27069 in the 
CLPTM1L gene was also replicated in invasive cervical 
cancer (p=2·54 × 10–⁷), CIN3 (p=0·04), and cervical 
dysplasia (p=0·0004) phenotypes.
In the mendelian randomisation, the strongest asso-
ciations with risk of cervical cancer were observed for 
smoking (OR 2·46, 95% CI 1·64–3·69) and number 
of sexual partners (1·95, 1·44–2·63; figure 3). We 
additionally identified a protective effect for older age at 
first pregnancy (0·80, 0·68–0·95; figure 3; appendix 
p 114). Sensitivity analyses using weighted-median and 
mendelian randomisation-Presso confirmed consistent 
effect sizes with the main analysis based on inverse 
variance weighting (appendix p 115). In attenuation 
analyses to account for potential pleiotropic effects, we 
found that the effect of age at first pregnancy was 
independent of the number of sexual partners as there 
was no attenuation for age at first pregnancy when 
accounting for number of sexual partners (appendix p 116). 
In the multivariable mendelian ran domisation model 
including both smoking and number of sexual partners, 
the effect of smoking did attenuate when accounting for 
the number of sexual partners, but remained significant 
(OR 1·74, 95% CI 1·08–2·81; appendix p 160).
Discussion
In this study, we present results from the largest GWAS 
to our knowledge so far on this subject, analysing cervical 
cancer phenotypes in more than 150 314 women of 
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Figure 3: Mendelian 
randomisation analysis of 
exposures associated with 
CIN3 and invasive cervical 
cancer
(A) Forest plot shows inverse 
variance weighted mendelian 
randomisation for all identified 
known environmental risk or 
protective factors for cervical 
cancer with available GWAS, 
to determine effect sizes by 
OR and 95% CI (x-axis; n=3). 
(B) Three mendelian 
randomisation exposures 
(x-axis, lifetime smoking 
index; number of sexual 
partners; age of first 
pregnancy) found to have a 
significant association with 
cervical cancer (y-axis). 
Each blue point represents a 
genetic variant used as an 
instrumental variable in the 
mendelian randomisation 
analysis and error bars show 
standard errors of genetic 
associations. The dark blue 
trendline represents the causal 
effect estimate from the 
inverse variance weighting 
mendelian randomisation on 
the β scale. CIN3=cervical 
intraepithelial neoplasia 
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European ancestry and over 9 million imputed and 
genotyped genetic variants. We provide evidence for a 
strong association at six independent loci in the PAX8, 
CLPTM1L, and HLA regions in the UK Biobank. We 
were able to replicate three SNPs in PAX8 (rs10175462), 
CLPTM1L (rs27069), and HLA-DQA1 (rs9272050) in an 
independent Finnish dataset of 4246 cervical dysplasia 
cases, 298 CIN3 cases, and 1648 cervical cancer cases 
(FinnGen).
Previous GWASs have been limited by the modest 
sample sizes and rarity of invasive cervical cancer; 
cervical disease phenotypes have been largely dominated 
by precancerous disease with no separate analyses of 
cancers. Imputations to permit expansion of studied loci 
have rarely been done, with the exception of the HLA 
region.10,13,16 Furthermore, the gene–environment inter-
action has not to date been adequately explored in cervical 
cancer, and our mendelian randomisation supported a 
risk-increasing effect of smoking, and number of sexual 
partners, and a protective effect of older age at first 
pregnancy on cervical cancer.
Our results in the HLA region are consistent with 
previous GWASs in cervical cancer, where allelic variation 
has been reported for HLA-DRB1,10,12,14,16 HLA-DQA1,12 
HLA-DQB1,10,16 HLA-DPB1,13 HLA-DPB2,13 and HLA-B,16 
and both protective and risk haplotypes have been 
described. Associations at the nearby MICA gene have 
also been replicated.12 HLA-DRB, HLA-DQA1, and MICA 
genes have important roles in the adaptive immune 
response to infection—coding for MHC class I and II 
alleles, which are responsible for antigen processing and 
exogeneous peptide presentation. Such responses are 
particularly vital in the mediation of T-cell mediated 
activity and cytotoxicity, which are known to have key roles 
in immune responses to both HPV infection and tumour 
cells.17 The HLA region is notorious for its complex linkage 
disequilibrium structure. Although we present four 
independent SNPS that have not been previously reported, 
linkage disequilibrium patterns from our analysis suggest 
high linkage with known variants. Our results therefore 
probably provide a replication of allelic variation for 
HLA-DQA1, HLA-DQB1, HLA-B, and MICA. Notably, 
gene annotations for non-coding variants are not certain. 
Of interest is our novel report of the association at a rarer 
SNP rs9266183 (MAF 0·037; HLA-B), which represents a 
missense variant resulting in a codon shift and amino acid 
change. Alteration of this allele might result in a shift in 
peptide presentation properties, distorting the T-cell 
response to HPV infection.18 Owing to the lower MAF, 
this association has probably gone undetected in previous 
smaller studies. Despite the growing number of HLA 
associations reported for cervical cancer, minimal 
laboratory validation has been done; given an anticipated 
coding effect, rs926618 would be one of the most 
interesting targets for further functional analyses.
To our knowledge, no SNPs outside of the HLA region 
have been validated in European populations, before this 
study. Although previous candidate gene studies of 
cervical cancer have explored regions related to immune 
function, cell cycle control, DNA repair, and other carci-
nogenic processes and identified genetic asso ciations 
including CTLA4, FANCA, OAS3, SULF1, IFNG, DUT, 
DMC1, GTF2H4 and EVER1/2,19 ERAP1, LMP7 and 
TAP2, TP53, TERT, IL10,20 and IL17 and TNF,21 these 
findings have not been replicated in larger cohorts. In 
Chinese populations, GWAS-detected loci in EXOC1 and 
GSDMB genes are suspected to influence immune 
response to viral infection.13 Whereas a Japanese GWAS 
reported an association with ARRDC3, and further 
evidence from gene knockdown in HeLa cells that 
genetic variation might affect HPV entry to cells.14
We identified novel variants in PAX8 and CLPTM1L 
intronic regions in UK Biobank samples, which were 
replicated in the FinnGen dataset of cervical cancer 
phenotypes. Our functional analysis showed how these 
associations might represent carcinogenic or immune 
function pathways. The strongest association at the PAX8 
locus was an indel (del:rs35724515), which was in perfect 
linkage disequilibrium with the lead SNP rs10175462. 
Enrichment for rs10175462 in cervical cancer tissue was 
colocalised with an eQTL, and the strongest effects were 
observed at LOC654433, suggesting long-range epigenetic 
regulation silencing might be controlling expression.22 
Specifically, decreased expression of the whole region was 
associated with a protective effect in the presence of the 
alternative T allele. Variant rs10175462 might be tagging 
the deletion variant rs35724515, resulting in decreased 
PAX8 expression leading to a protective effect due to 
reduced uncontrolled cell growth and anti-apoptosis 
associated with PAX8 overexpression.23,24
Genetic variation detected at the CLPTM1L locus offers 
additional insight into potential carcinogenic pathways 
in HPV-driven cancers. CLPTM1L codes for a trans-
membrane protein and has been linked to cell growth 
promotion in non-cervical tumours,25 and altering 
cisplatin-mediated apoptosis when overexpressed.26 
CLPTM1L’s previous association with multiple mucosal 
and HPV-driven cancers suggests a role in regulation of 
viral transmission across epithelial barriers. Additional 
investigations of anti-CLPTM1L monoclonal antibodies 
in chemoresistant lung and pancreatic cancers suggest 
that CLPTM1L is a potential novel target for cancer 
therapeutics in various cancers.27
Our main GWAS was based on a broad definition of 
cervical cancer including both invasive cervical cancer and 
CIN3 case samples. Conditional analyses of the CIN3 or 
invasive cervical cancer phenotype identified four 
associated SNPs that could be viewed as inde pendent 
genetic markers of cervical cancer that comple mentarily 
contribute to the explanation of the disease outcome. 
Although CIN3 is considered the immediate cancer 
precursor, it is estimated that 30% of women with CIN3 
develop invasive cervical cancer within 10–15 years.28 In 
the subgroup of invasive cervical cancer cases alone, there 
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was a strong attenuation of the associations in HLA and 
PAX8 regions, which were not found to be genome-wide 
associated with the outcome. Similar attenuation was 
observed for the associations linking genetic variants in 
the PAX8 gene with the CIN3 outcome, both in our UK 
Biobank participants and in the replication cohort. 
Conversely, a strong and broad signal was observed in the 
chromosome 6 HLA region in relation to the CIN3 only 
outcome. Meanwhile, only one SNP (rs9272245, HLA) 
remained significant after our conditional analyses, hence 
supporting the existence of a single strong genetic signal 
associated with CIN3. This is the first study with adequate 
power to separately explore variation in the invasive cancer 
phenotype alone. These results provide some evidence of 
histological heterogeneity, with the HLA region being 
more strongly associated with non-progressive preinvasive 
lesions, rather than invasive cervical cancer, whereas 
PAX8 signals might only be detectable in larger sample 
sizes as shown in the invasive cervical cancer phenotype 
of the replication cohort. In our replication cohort, due to 
the original phenotype coding, the analyses pooling all 
cases included less severe phenotypes (CIN1 and CIN2). 
Inclusion of these phenotypes might have increased the 
heterogeneity of the cases and diluted the estimated 
effects. Longitudinal study of CIN lesions could reveal 
valuable information on genetic variance associated with 
more aggressive phenotypes.
Results from our mendelian randomisation models 
confirmed previous observations that smoking and an 
increased number of sexual partners are risk factors for 
CIN and cervical cancer. Indeed, smoking cessation advice 
is routinely offered at colposcopy clinics. We did find, 
however, that when applying a multivariable mendelian 
randomisation analysis, the effect of smoking attenuated 
when accounting for the number of sexual partners, 
suggesting that the strong associations seen with smoking 
might in part be related to increased lifetime HPV 
exposure from other risky behaviours. We further 
confirmed that the effect of young age at first pregnancy 
was not attenuated when controlling for number of sexual 
partners, suggesting a possible independent effect of 
young pregnancy on cancer risk, potentially through 
mechanisms of early cervical trauma or early hormonal 
changes. We were unable, however, to confirm that risk 
associated with younger age of first pregnancy was not a 
surrogate for young age of HPV exposure and age at first 
sexual intercourse, or related to higher parity. Previous 
studies have shown a disappearance in effect after 
controlling for parity,29 although in a large pooled analysis 
the effect of early pregnancy on cervical cancer remained 
after adjusting for sexual habits (lifetime sexual partners 
and age at first sexual intercourse).6
HPV status was not available in the UK Biobank due to 
the invasive nature of sampling healthy volunteers and 
the absence of HPV-based screening data, which has only 
recently been introduced in most countries. Furthermore, 
HPV status at a given timepoint would be an unreliable 
surrogate of exposure or clearance, and serum antibodies 
tests have variable accuracy and are not commercially 
available. To reduce potential for this complex 
confounding, our control group comprised only women 
with no previous abnormal screening history—because 
this population was likely to have been exposed to HPV 
without developing any cervical lesion. Future adequately 
powered studies should investigate differential genetic 
variation in the presence of a known screening history of 
HPV clearance or persistence. The UK Biobank only had 
a sufficient number of case samples to study European 
ancestry. Given the high burden of cervical malignancy 
in non-European populations, future studies should 
further explore genetic variation in other ethnicities, 
particularly Black and south Asian populations. Although 
this was the first mendelian randomisation, the analysis 
was based on publicly available summary-level data—we 
used female sex-specific data on genetic associations 
where possible, but such data were not available for all 
exposures considered (smoking and number of sexual 
partners). For some of the exposures, there was overlap 
in samples for the two-sample mendelian randomisation 
design. However, since we based our analysis on genetic 
variants that are strongly associated with the exposure, 
representing strong instrumental variables, the induced 
bias can be considered negligible.
Our findings offer exciting insights into the genetic 
predisposition of the cervical cancer trait. This study 
supports a complex neoplastic model related to both 
altered immune response and carcinogenic processes in 
the presence of high-risk HPV. Investigations that 
integrate the study of host susceptibility with viral genetic 
variation,30 along with epigenetic behaviour, could further 
elucidate the differential risk related to complex host–
viral interactions. Meanwhile, further investigation of the 
functional effects of loci, within and outside of the HLA, 
is needed to better understand the pathogenesis of 
cervical neoplasia, and implications for potential 
therapeutic targets in women with cervical preinvasive 
and cancerous lesions.
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